About
Kestrel Therapeutics is a clinical-stage biotechnology company developing small molecule inhibitors that target KRAS mutations to treat various KRAS-driven cancers, including advanced solid tumors.
Explore Kestrel Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.